※The timeline may change depending on each project.
-
-
In need of codon optimization and UTR?
Tailored mRNA design
at your fingertips -
In need of clinical or commercial mRNA/LNP?
Brand new cGMP facility dedicated to manufacturing of mRNA/LNP
-
In need of rapid development?
Achieve success in just 3 months - the fastest route to your development journey
-
In need of simplification?
One stop solution to simplify outsourcing
-
In need of large production capacity?
Up to 100g mRNA batch
Why ARCALIS?
Your product, our passion and expertise
ARCALIS’ Minamisoma Facility
ARCALIS has built a cGMP mRNA drug substance manufacturing facility in Minamisoma City in July 2023, and the world's first approved product applying a self-amplifying, mRNA technology vaccine it's planning to commercialize from 2024.The Minamisoma campus will also include a separate drug product manufacturing facility. Once completed in 2026, ARCALIS can offer one-stop manufacturing and release testing of mRNA vaccines and therapeutics.
